Healthcare
from24/7 Wall St.
3 days agoUnited Therapeutics Gets Dual Target Hikes From BofA and Wells Fargo
Positive TETON-1 trial data expands Tyvaso's market potential into idiopathic pulmonary fibrosis, prompting price target increases from major Wall Street firms.